I'm guessing that perhaps they think either it's going to get harder to keep hiring sales people and growing by the same % each year or that they will have captured the easiest part of the addressable market and they could convert distributed markets into direct sales. But I think that addressaable market is underestimated. Perhaps the best indicator is the number of publications about Novosorb. If revenue grows by 50% in 2025 and 2026 then we'd be at $225m not just $180m in 2026
Ann: Macquarie Australia Conference - Presentation, page-28
-
- There are more pages in this discussion • 21 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.60 |
Change
-0.010(0.38%) |
Mkt cap ! $1.787B | |||
| Open | High | Low | Value | Volume |
| $2.59 | $2.61 | $2.56 | $959.9K | 371.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 29 | 18254 | $2.59 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.60 | 54253 | 23 |
View Market Depth
| Last trade - 14.18pm 30/07/2024 (20 minute delay) ? |
| PNV (ASX) Chart |